Allergic Rhinitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Allergic Rhinitis - Pipeline Review, H2 2018’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

- The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

- The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accolade Pharmaceuticals LLC

AFFiRiS AG

ALK-Abello AS

AlleCures Inc

AOBiome LLC

ASIT Biotech SA

Chong Kun Dang Pharmaceutical Corp

Chrysalis BioTherapeutics Inc

CSPC Pharmaceutical Group ...

Accolade Pharmaceuticals LLC

AFFiRiS AG

ALK-Abello AS

AlleCures Inc

AOBiome LLC

ASIT Biotech SA

Chong Kun Dang Pharmaceutical Corp

Chrysalis BioTherapeutics Inc

CSPC Pharmaceutical Group Limited

Daewon Pharm Co Ltd

Fountain Biopharma Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HAL Allergy BV

Hanlim Pharm Co Ltd

iCo Therapeutics Inc

Inimmune Corp

Intrommune Therapeutics

Laboratorios LETI SL

Marinomed Biotech AG

Mitsubishi Tanabe Pharma Corp

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Regeneron Pharmaceuticals Inc

Stallergenes Greer plc

The Geneva Biotech Center SA

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Allergic Rhinitis – Overview 6

Allergic Rhinitis – Therapeutics Development 7

Allergic Rhinitis – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Allergic Rhinitis – Overview 6

Allergic Rhinitis – Therapeutics Development 7

Allergic Rhinitis – Therapeutics Assessment 15

Allergic Rhinitis – Companies Involved in Therapeutics Development 23

Allergic Rhinitis – Drug Profiles 36

Allergic Rhinitis – Dormant Projects 116

Allergic Rhinitis – Discontinued Products 123

Allergic Rhinitis – Product Development Milestones 125

Appendix 135

List of Tables

List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Allergic Rhinitis – Pipeline by Accolade Pharmaceuticals LLC, H2 2018

Allergic Rhinitis – Pipeline by AFFiRiS AG, H2 2018

Allergic Rhinitis – Pipeline by ALK-Abello AS, H2 2018

Allergic Rhinitis – Pipeline by AlleCures Inc, H2 2018

Allergic Rhinitis – Pipeline by AOBiome LLC, H2 2018

Allergic Rhinitis – Pipeline by ASIT Biotech SA, H2 2018

Allergic Rhinitis – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Allergic Rhinitis – Pipeline by Chrysalis BioTherapeutics Inc, H2 2018

Allergic Rhinitis – Pipeline by CSPC Pharmaceutical Group Limited, H2 2018

Allergic Rhinitis – Pipeline by Daewon Pharm Co Ltd, H2 2018

Allergic Rhinitis – Pipeline by Fountain Biopharma Inc, H2 2018

Allergic Rhinitis – Pipeline by GlaxoSmithKline Plc, H2 2018

Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Allergic Rhinitis – Pipeline by HAL Allergy BV, H2 2018

Allergic Rhinitis – Pipeline by Hanlim Pharm Co Ltd, H2 2018

Allergic Rhinitis – Pipeline by iCo Therapeutics Inc, H2 2018

Allergic Rhinitis – Pipeline by Inimmune Corp, H2 2018

Allergic Rhinitis – Pipeline by Intrommune Therapeutics, H2 2018

Allergic Rhinitis – Pipeline by Laboratorios LETI SL, H2 2018

Allergic Rhinitis – Pipeline by Marinomed Biotech AG, H2 2018

Allergic Rhinitis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Allergic Rhinitis – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018

Allergic Rhinitis – Pipeline by Pfizer Inc, H2 2018

Allergic Rhinitis – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Allergic Rhinitis – Pipeline by Stallergenes Greer plc, H2 2018

Allergic Rhinitis – Pipeline by The Geneva Biotech Center SA, H2 2018

Allergic Rhinitis – Pipeline by Xencor Inc, H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..1), H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..2), H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..3), H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..4), H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..5), H2 2018

Allergic Rhinitis – Dormant Projects, H2 2018 (Contd..6), H2 2018

Allergic Rhinitis – Discontinued Products, H2 2018

Allergic Rhinitis – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number ...

List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 15

Number of Products by Top 10 Targets, H2 2018 20

Number of Products by Stage and Top 10 Targets, H2 2018 20

Number of Products by Top 10 Mechanism of Actions, H2 2018 22

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 22

Number of Products by Routes of Administration, H2 2018 24

Number of Products by Stage and Routes of Administration, H2 2018 24

Number of Products by Molecule Types, H2 2018 26

Number of Products by Stage and Molecule Types, H2 2018 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports